• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨肉瘤幸存者的继发原发性肿瘤;在 30 年的随访后和最新的治疗时代,风险仍然增加,一项全国范围内基于人群的研究。

Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study.

机构信息

Department of Molecular Medicine and Surgery (MMK), K1, Orthopaedics, Karolinska Universitetssjukhuset, 17176, Solna, Sweden.

Department of Medical Epidemiology and Biostatistics (MEB), C8, Biostatistics, Box 210 171 77, Stockholm, Sweden.

出版信息

Br J Cancer. 2020 Apr;122(8):1242-1249. doi: 10.1038/s41416-020-0748-3. Epub 2020 Feb 18.

DOI:10.1038/s41416-020-0748-3
PMID:32066914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7156510/
Abstract

BACKGROUND

The long-term risks and time trends of subsequent primary neoplasms (SPNs) among Ewing (ES) and osteosarcoma (OS) survivors are not fully understood.

METHODS

We performed a nationwide study of all ES and OS patients identified in the Swedish Cancer Registry from 1958 to 2015 with up to 58 years of follow-up. The risk of SPN was compared with that of the general population using standardised incidence ratios (SIRs) and absolute excess risks (AERs).

RESULTS

One hundred and fifteen SPNs were diagnosed among 1779 patients with ES or OS, yielding an overall SIR of 2.3 (95% confidence interval (CI), 1.9-2.7). The risk remained significantly increased in the latest treatment era (SIR 2.0; 95% CI, 1.1-3.5). The highest absolute excess risks (AER) was due to breast cancer (AER 15.2/10,000 person-years; 95% CI, 5.0-29.8) followed by female genital malignancies (AER 9.5/10,000 person-years; 95% CI, 2.4-21.5). The excess breast cancer risk among ES survivors was noted also after 30 years of follow-up with 127 extra breast cancers/10,000 person-years (95% CI, 6.6-419).

CONCLUSIONS

Breast- and female genital malignancies contribute most to the excess risk of SPN among ES and OS survivors. Importantly, excess risks did not decline over calendar time or long-term follow-up.

摘要

背景

尤文氏肉瘤(ES)和骨肉瘤(OS)幸存者的后续原发性肿瘤(SPN)的长期风险和时间趋势尚不完全清楚。

方法

我们对 1958 年至 2015 年期间在瑞典癌症登记处登记的所有 ES 和 OS 患者进行了一项全国性研究,随访时间长达 58 年。使用标准化发病率比(SIR)和绝对超额风险(AER)比较 SPN 的风险与一般人群的风险。

结果

在 1779 名 ES 或 OS 患者中诊断出 115 例 SPN,总体 SIR 为 2.3(95%置信区间(CI),1.9-2.7)。在最新的治疗时代,风险仍然显著增加(SIR 2.0;95%CI,1.1-3.5)。最高的绝对超额风险(AER)归因于乳腺癌(AER 15.2/10,000 人年;95%CI,5.0-29.8),其次是女性生殖系统恶性肿瘤(AER 9.5/10,000 人年;95%CI,2.4-21.5)。在随访 30 年后,ES 幸存者的乳腺癌风险仍然过高,每 10,000 人年有 127 例额外乳腺癌(95%CI,6.6-419)。

结论

乳腺癌和女性生殖系统恶性肿瘤是 ES 和 OS 幸存者 SPN 超额风险的主要原因。重要的是,超额风险并未随着时间推移或长期随访而下降。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98d3/7156510/3a7c89e9ad48/41416_2020_748_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98d3/7156510/3a7c89e9ad48/41416_2020_748_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98d3/7156510/3a7c89e9ad48/41416_2020_748_Fig1_HTML.jpg

相似文献

1
Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study.骨肉瘤幸存者的继发原发性肿瘤;在 30 年的随访后和最新的治疗时代,风险仍然增加,一项全国范围内基于人群的研究。
Br J Cancer. 2020 Apr;122(8):1242-1249. doi: 10.1038/s41416-020-0748-3. Epub 2020 Feb 18.
2
Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe.欧洲 69460 例儿童癌症 5 年幸存者的软组织肉瘤风险。
J Natl Cancer Inst. 2018 Jun 1;110(6):649-660. doi: 10.1093/jnci/djx235.
3
Long-term risks of subsequent primary neoplasms among survivors of childhood cancer.儿童癌症幸存者继发原发性肿瘤的长期风险。
JAMA. 2011 Jun 8;305(22):2311-9. doi: 10.1001/jama.2011.747.
4
Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup.欧洲在诊儿童癌症后 5 年生存者 69460 例中继发原发性白血病的风险:PanCareSurFup 内的队列研究。
Eur J Cancer. 2019 Aug;117:71-83. doi: 10.1016/j.ejca.2019.05.013. Epub 2019 Jun 28.
5
Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer - A national cohort study.儿童癌症后早期第二原发肿瘤的风险因素:癌症易感性综合征 - 一项全国性队列研究。
Eur J Cancer. 2021 Mar;145:71-80. doi: 10.1016/j.ejca.2020.11.042. Epub 2021 Jan 7.
6
Long-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study.儿童骨肉瘤幸存者的长期不良结局:英国儿童癌症幸存者研究
Br J Cancer. 2015 Jun 9;112(12):1857-65. doi: 10.1038/bjc.2015.159. Epub 2015 May 19.
7
Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada.加拿大不列颠哥伦比亚省儿童和青少年癌症5年幸存者中发生第二种恶性肿瘤的风险。
Pediatr Blood Cancer. 2007 Apr;48(4):453-9. doi: 10.1002/pbc.20921.
8
Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort.1976年后被诊断为恶性骨肿瘤的儿童、青少年和青年中的第二原发性恶性肿瘤:儿童肿瘤学组队列研究随访
Cancer. 2008 Nov 1;113(9):2597-604. doi: 10.1002/cncr.23860.
9
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.视网膜母细胞瘤幸存者发生二次恶性肿瘤的风险:超过40年的随访
J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9. doi: 10.1093/jnci/djn394. Epub 2008 Dec 9.
10
Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study.尤因肉瘤成年幸存者的纵向随访:来自儿童癌症幸存者研究的报告。
Cancer. 2017 Jul 1;123(13):2551-2560. doi: 10.1002/cncr.30627. Epub 2017 Feb 21.

引用本文的文献

1
UK guidelines for the management of bone sarcomas.英国骨肉瘤管理指南。
Br J Cancer. 2025 Jan;132(1):32-48. doi: 10.1038/s41416-024-02868-4. Epub 2024 Nov 16.
2
3D-Printed Talus-Calcaneus Prosthesis in Treating Ewing's Sarcoma: A Case Report.3D打印距骨-跟骨假体治疗尤因肉瘤:1例报告
Orthop Surg. 2025 Jan;17(1):288-294. doi: 10.1111/os.14279. Epub 2024 Nov 11.
3
Sacral Ewing sarcoma with rib, lung, and multifocal skull metastases: A rare case report and review of treatments.伴有肋骨、肺及多灶性颅骨转移的骶骨尤因肉瘤:一例罕见病例报告及治疗综述

本文引用的文献

1
New malignancies following childhood cancer in the United States, 1973-2002.1973 - 2002年美国儿童癌症后的新发恶性肿瘤
Int J Cancer. 2007 Nov 15;121(10):2233-40. doi: 10.1002/ijc.22827.
2
Cancer in the Nordic countries, 1981-86. A joint publication of the five Nordic Cancer Registries.北欧国家的癌症情况,1981 - 1986年。北欧五个癌症登记处的联合出版物。
APMIS Suppl. 1992;31:1-194.
Front Oncol. 2022 Sep 8;12:933579. doi: 10.3389/fonc.2022.933579. eCollection 2022.
4
Current Status of Management and Outcome for Patients with Ewing Sarcoma.尤因肉瘤患者的治疗现状与预后
Cancers (Basel). 2021 Mar 10;13(6):1202. doi: 10.3390/cancers13061202.
5
Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors.CRISPR/Cas9 在恶性肌肉骨骼肿瘤研究中的应用。
BMC Musculoskelet Disord. 2021 Feb 5;22(1):149. doi: 10.1186/s12891-021-04020-2.
6
MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1.miR-363 通过与 NOB1 结合抑制骨肉瘤细胞迁移、侵袭和上皮-间充质转化。
World J Surg Oncol. 2020 May 1;18(1):83. doi: 10.1186/s12957-020-01859-y.